secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2024-09-19T23:59:59+00:00
Accession:  0001104659-24-101342
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute reports Q4 FY2024 net loss of $23M; FDA lifts partial clinical hold on ersodetug
--------------------------------------------------------------------------------

- Q4 net loss $23.0M vs $12.7M prior year; full year net loss $68.5M vs $51.8M.
- Cash and investments $127.1M at June 30, 2024, up from $118.4M year-over-year.
- FDA lifts partial clinical holds on ersodetug for congenital HI; U.S. enrollment in Phase 3 sunRIZE expected early 2025.
- Phase 3 study for tumor HI to begin H1 2025; topline results expected mid-2026.
- Phase 2 RZ402 for DME met primary endpoints; partnering discussions ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924101342/0001104659-24-101342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924101342/tm2424269d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-101342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer